Cargando…

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma

Detalles Bibliográficos
Autores principales:	Margolin, Kim, Wong, Hing C, Morishima, Chihiro, Hernandez, Liza, Ernstoff, Marc, Rhode, Peter R, Waldmann, Thomas A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288745/ http://dx.doi.org/10.1186/2051-1426-2-S3-P79

Ejemplares similares

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
por: Chen, Xiaoyue, et al.
Publicado: (2015)

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
por: Morishima, Chihiro, et al.
Publicado: (2014)

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
por: Morishima, Chihiro, et al.
Publicado: (2015)

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
por: Drusbosky, Leylah, et al.
Publicado: (2020)

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
por: Kim, Peter S., et al.
Publicado: (2016)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
por: Basher, Fahmin, et al.
Publicado: (2015)

Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
por: Gomes-Giacoia, Evan, et al.
Publicado: (2014)

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2020)

Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells
por: Van der Meer, J. M. R., et al.
Publicado: (2021)

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity
por: Bailey, Cavan P., et al.
Publicado: (2017)

IL-15 and N-803 for HIV Cure Approaches
por: Howard, J. Natalie, et al.
Publicado: (2023)

The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques
por: Webb, Gabriela M., et al.
Publicado: (2020)

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
por: Chen, Wujun, et al.
Publicado: (2022)

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques
por: McBrien, Julia B., et al.
Publicado: (2020)

Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma
por: Dennis, Lucas, et al.
Publicado: (2015)

Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection
por: Harwood, Olivia, et al.
Publicado: (2021)

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
por: Knudson, Karin M., et al.
Publicado: (2019)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

Oktett, D. 803
por: Schubert, Franz, 1797-1828
Publicado: (1988)

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
por: Jochems, Caroline, et al.
Publicado: (2018)

Are there superagonists for calcium-activated potassium channels?
por: Brown, Brandon M., et al.
Publicado: (2017)

Schedule of experiment R803
por: Jarlskog, G
Publicado: (1973)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

Oktett F-Dur, D. 803= octet in F major D 803
por: Schubert, Franz 1797-1828
Publicado: (2014)

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
por: Lui, Grace, et al.
Publicado: (2023)

Octets D. 803 , D. 72
por: Schubert, Franz, 1797-1828
Publicado: (1993)

4308 DEEP-PRIMED IL-15 SUPERAGONIST IMPROVES ANTIVIRAL EFFICACY OF HIV-SPECIFIC CD8(+) T-CELLS IN HUMANIZED MOUSE MODEL
por: McCann, Chase Daniel, et al.
Publicado: (2020)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
por: Fousek, Kristen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a7j4nphrk60ld05q338ef1pls8